407 related articles for article (PubMed ID: 36875849)
1. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.
Maestri M; Santopaolo F; Pompili M; Gasbarrini A; Ponziani FR
Front Nutr; 2023; 10():1110536. PubMed ID: 36875849
[TBL] [Abstract][Full Text] [Related]
2. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
[TBL] [Abstract][Full Text] [Related]
3. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
5. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.
Xue L; Deng Z; Luo W; He X; Chen Y
Front Cell Infect Microbiol; 2022; 12():759306. PubMed ID: 35860380
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
[TBL] [Abstract][Full Text] [Related]
9. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
10. Fecal Microbiota Transplantation in NAFLD Treatment.
Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
[No Abstract] [Full Text] [Related]
11. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
13. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
14. Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials.
Cao C; Shi M; Wang X; Yao Y; Zeng R
Front Nutr; 2023; 10():1155306. PubMed ID: 37457967
[TBL] [Abstract][Full Text] [Related]
15. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
16. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation.
Chen L; Kan J; Zheng N; Li B; Hong Y; Yan J; Tao X; Wu G; Ma J; Zhu W; Sheng L; Chen L; Li B; Zhong J; Du J; Li H
Phytomedicine; 2021 Oct; 91():153693. PubMed ID: 34403877
[TBL] [Abstract][Full Text] [Related]
17. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
Wang T; Ishikawa T; Sasaki M; Chiba T
Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
[TBL] [Abstract][Full Text] [Related]
18.
Riezu-Boj JI; Barajas M; Pérez-Sánchez T; Pajares MJ; Araña M; Milagro FI; Urtasun R
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558371
[TBL] [Abstract][Full Text] [Related]
19. Role and effective therapeutic target of gut microbiota in NAFLD/NASH.
Liu Q; Liu S; Chen L; Zhao Z; Du S; Dong Q; Xin Y; Xuan S
Exp Ther Med; 2019 Sep; 18(3):1935-1944. PubMed ID: 31410156
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
